Telix Pharmaceuticals Limited (TLPPF)

Market Cap	5.66B
Revenue (ttm)	484.69M
Net Income (ttm)	30.89M
Shares Out	n/a
EPS (ttm)	0.09
PE Ratio	183.35
Forward PE	48.07
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	2,927
Open	16.50
Previous Close	16.20
Day's Range	16.50 - 16.50
52-Week Range	11.01 - 24.85
Beta	2.41
RSI	44.63
Earnings Date	May 22, 2025

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis o...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 234
• Stock Exchange: OTCMKTS
• Ticker Symbol: TLPPF

Financial Performance

In 2024, Telix Pharmaceuticals's revenue was 783.21 million, an increase of 55.85% compared to the previous year's 502.55 million. Earnings were 49.92 million, an increase of 857.95%.

Financial numbers in AUD